Pharmacy Choice

PharmacyChoice.com

Pharmacy Choice, Inc. is an online pharmacy community and application service provider/professional services company serving the pharmaceutical industry. Our pharmacy community web portal provides pharmacists, pharmacy technicians, pharmacy job seekers, students and others with the most comprehensive suite of web-based tools and info available, including pharmacy career services, RX drug information and continuing education for pharmacists.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

APT THERAPEUTICS INC. ENTERS WORLDWIDE COLLABORATION, OPTION AND ASSET PURCHASE AGREEMENT FOR INVESTIGATION OF HUMAN APYRASE THERAPY

Pharmacy Choice | January 18, 2017

news image

By a News Reporter-Staff News Editor at Biotech Week APT Therapeutics, Inc., a privately-held biopharmaceutical company, announced a research collaboration, option and asset purchase agreement with AstraZeneca. APT Therapeutics has applied proprietary protein engineering strategies to develop APT102, an innovative human apyrase therapy for the treatment of thrombotic diseases. Uniquely different than current FDA-approved antithrombotic drugs that can increase bleeding risk, APT102 attenuated clo...

Read More

AKEBIA AND VIFOR PHARMA ANNOUNCE EXCLUSIVE LICENSE AGREEMENT TO PROVIDE VADADUSTAT TO FRESENIUS MEDICAL CARE IN THE U.S. UPON FDA APPROVAL

Pharmacy Choice | June 02, 2017

news image

By a News Reporter-Staff News Editor at Health & Medicine Week Akebia Therapeutics, Inc. (NASDAQ:AKBA) and Vifor Pharma Group. announced they have entered into an exclusive license agreement to sell vadadustat to Fresenius Medical Care dialysis clinics in the United States upon approval by the U.S. Food and Drug Administration (FDA)....

Read More

PATENT ISSUED FOR DRUG DELIVERY TREATMENT DEVICE

Pharmacy Choice | June 19, 2017

news image

Reporters obtained the following quote from the background information supplied by the inventors: "This disclosure relates generally to methods and devices for use in treating various ocular diseases. Glaucoma is caused by a number of different eye diseases which can produce increased intraocular pressure (IOP) in the eye. The increased pressure is often caused by a backup of aqueous humour within the eye. Over time, the increased pressure can cause damage to the optic nerve, which can lead to b...

Read More

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

news image

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More
news image

APT THERAPEUTICS INC. ENTERS WORLDWIDE COLLABORATION, OPTION AND ASSET PURCHASE AGREEMENT FOR INVESTIGATION OF HUMAN APYRASE THERAPY

Pharmacy Choice | January 18, 2017

By a News Reporter-Staff News Editor at Biotech Week APT Therapeutics, Inc., a privately-held biopharmaceutical company, announced a research collaboration, option and asset purchase agreement with AstraZeneca. APT Therapeutics has applied proprietary protein engineering strategies to develop APT102, an innovative human apyrase therapy for the treatment of thrombotic diseases. Uniquely different than current FDA-approved antithrombotic drugs that can increase bleeding risk, APT102 attenuated clo...

Read More
news image

AKEBIA AND VIFOR PHARMA ANNOUNCE EXCLUSIVE LICENSE AGREEMENT TO PROVIDE VADADUSTAT TO FRESENIUS MEDICAL CARE IN THE U.S. UPON FDA APPROVAL

Pharmacy Choice | June 02, 2017

By a News Reporter-Staff News Editor at Health & Medicine Week Akebia Therapeutics, Inc. (NASDAQ:AKBA) and Vifor Pharma Group. announced they have entered into an exclusive license agreement to sell vadadustat to Fresenius Medical Care dialysis clinics in the United States upon approval by the U.S. Food and Drug Administration (FDA)....

Read More
news image

PATENT ISSUED FOR DRUG DELIVERY TREATMENT DEVICE

Pharmacy Choice | June 19, 2017

Reporters obtained the following quote from the background information supplied by the inventors: "This disclosure relates generally to methods and devices for use in treating various ocular diseases. Glaucoma is caused by a number of different eye diseases which can produce increased intraocular pressure (IOP) in the eye. The increased pressure is often caused by a backup of aqueous humour within the eye. Over time, the increased pressure can cause damage to the optic nerve, which can lead to b...

Read More
news image

GROUND-BREAKING COLLABORATION TO OFFER NEW HEART DISEASE DRUG TO NHS PATIENTS

Pharmacy Business | January 14, 2020

The government on Monday announced a collaboration with Novartis to launch a clinical trial for ‘yet to be approved’ drug inclisiran. The drug could benefit thousands of patients at risk of heart disease in coming years. The ground-breaking collaboration includes Novartis, NHS England and the National Institute for Health Research (NIHR) and Oxford University. The Department of Health and Social Care (DHSC) expects this to position the UK as a world-leading destination to develop cut...

Read More